A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Yung, W K A, Albright, R E, Olson, J, Fredericks, R, Fink, K, Prados, M D, Brada, M, Spence, A +14 more·2000·British Journal of Cancer

DOI 10.1054/bjoc.2000.1316

Cited by (928)

Items 101–200 of 928

Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
Roger Henriksson, Thomas Asklund, Hans Skovgaard Poulsen · 2011 · Journal of Neuro-Oncology
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, MARTIN J.B. TAPHOORN, Jonathan Steuve, Alba Ariela Brandes, Marie‐France Hamou, Antje Wick et al. · 2016 · Clinical Cancer Research
Mechanisms of Disease: temozolomide and glioblastoma—look to the future
Maciej M. Mrugała, Marc Charles Chamberlain · 2008 · Nature Clinical Practice Oncology
Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies
Sushma Kunwar · 2003 · Springer eBooks
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Wolfgang Wick, Joachim Peter Steinbach, Wilhelm Küker, JOHANNES DICHGANS, MAXIMILIAN BAMBERG, Michael Weller · 2004 · Neurology
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
W. C. Gunther, E Pawlak, Rosélia S. Damasceno, Hans Arnold, A. J. A. Terzis · 2003 · British Journal of Cancer
Central nervous system gliomas
Michele Reni, Elena A. Mazza, Silvia Matilde Zanon, Gemma Gatta, Charles J. Vecht · 2017 · Critical Reviews in Oncology/Hematology
Angiogenesis in pancreatic carcinoma
Shuichi Fujioka, Kazuhiko Yoshida, Satoru Yanagisawa, Makio Kawakami, Teruaki Aoki, Yoji Yamazaki · 2001 · Cancer
Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study
Kurt A. Jaeckle, Kenneth R. Hess, W.K. Alfred Yung, Harry S. Greenberg, Howard Alan Fine, David Schiff, Ian F. Pollack, John G. Kuhn, Karen Fink, Minesh P. Mehta et al. · 2003 · Journal of Clinical Oncology
A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas
Jeffrey J. Raizer, Sean Aaron Grimm, Marc Charles Chamberlain, Martin Kelly Nicholas, James P. Chandler, Kenji Muro, Steven Dubner, ALFRED W. RADEMAKER, Jaclyn J. Renfrow, Markus Bredel · 2010 · Cancer
Bevacizumab and daily temozolomide for recurrent glioblastoma
Annick Desjardins, David A. Reardon, April D. Sykes, Jennifer E. Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, James J. Vredenburgh · 2011 · Cancer
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Philip C. De Witt Hamer · 2010 · Neuro-Oncology
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis
Catherine A. McBain, Theresa A Lawrie, Ewelina Rogozińska, Ashleigh Kernohan, Tomos Robinson, Sarah Jefferies · 2021 · Cochrane Database of Systematic Reviews
Therapeutic options for recurrent malignant glioma
Maximilian Niyazi, Axel Siefert, Silke Birgit Schwarz, Ute Ganswindt, Friedrich-Wilhelm Kreth, Jörg‐Christian Tonn, Claus Belka · 2010 · Radiotherapy and Oncology
Glioma Therapy in Adults
Andrew David Norden, Patrick Yung Wen · 2006 · The Neurologist
Homing peptides as targeted delivery vehicles
Pirjo Maarit Laakkonen, Kirsi Vuorinen · 2010 · Integrative Biology
Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394
Stuart A. Grossman, Anne O’Neill, Margaret L. Grunnet, Minesh P. Mehta, James L. Pearlman, Henry Wagner, Mark R. Gilbert, Herbert B. Newton, Richard Hellman · 2003 · Journal of Clinical Oncology
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han, M. Ren, Wolfgang Wick, Lauren E. Abrey, A. Das, James Jin, David A. Reardon · 2013 · Neuro-Oncology
Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI
Girish Manohar Fatterpekar, Diogo Galheigo, Ashwatha Narayana, Glyn Johnson, Edmond A. Knopp · 2011 · American Journal of Roentgenology
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Roger Stupp, Fausto Roila · 2009 · Annals of Oncology
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Caroline Hertler, Patrick Roth, Wolfgang Wick, Natalie Schmidt, Ana‐Maria Florea, Manuela Silginer, Guido Reifenberger, Michael Weller · 2012 · Journal of Neurochemistry
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas
Clóvis Orlando da Fonseca, Gilberto Schwartsmann, Juliana de Saldanha da Gama Fischer, Janaína Nagel, Débora Omena Futuro, Thereza Quírico‐Santos, Cerli Rocha Gattass · 2008 · Surgical Neurology
Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report
Walter Stummer, Tobias J. Beck, Wolfgang Beyer, Jan Hendrik Mehrkens, Andreas Obermeier, Nima Etminan, Herbert G. Stepp, Jörg‐Christian Tonn, Reinhold Baumgartner, Jochen Wolfgang Herms et al. · 2007 · Journal of Neuro-Oncology
CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS
Michael A. Vogelbaum, John Howard Sampson, Sandeep Kunwar, Susan Marina Chang, Mark Edwin Shaffrey, Anthony L. Asher, Frederick F. Lang, David J. Croteau, Kristen Parker, Amy Y. Grahn et al. · 2007 · Neurosurgery
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew David Norden, Jan Drappatz, Alona Muzikansky, Karly David, Mary Gerard, M. Brenna McNamara, Phuong Phan, Ainsley Ross, Santosh Kesari, Patrick Yung Wen · 2008 · Journal of Neuro-Oncology
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W.K. Alfred Yung, James J. Vredenburgh, Timothy Francis Cloughesy, Phioanh Leia Nghiemphu, Barbara Jane Klencke, MARCEL R. GILBERT, David A. Reardon, Michael D. Prados · 2010 · Neuro-Oncology
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
Susan Marina Chang, Kathleen R. Lamborn, Mary K. Malec, David Allen Larson, William M. Wara, Penny K. Sneed, Jane E. Rabbitt, Margaretta Page, Martin Kelly Nicholas, Michael D. Prados · 2004 · International Journal of Radiation Oncology*Biology*Physics
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations
Olivier Louis Chinot, Maryline Barrié, Élisabeth Frauger, Henry Dufour, Dominique F. Figarella-Branger, Jacky Palmari, Diane Braguer, Khê Hoang‐Xuan, Karima Moktari, J.C. Peragut et al. · 2004 · Cancer
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
Michael Glantz, Marc Charles Chamberlain, Qin Liu, Norman Scott Litofsky, Lawrence David Recht · 2003 · Cancer
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
MARTIN J.B. TAPHOORN, Roger Henriksson, Andrew Bottomley, Timothy Francis Cloughesy, Wolfgang Wick, Warren P. Mason, Frank H. Saran, Ryo Nishikawa, Magalie Hilton, Christina Theodore‐Oklota et al. · 2015 · Journal of Clinical Oncology
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients
Markus Andreas Schaich, L. Kestel, Markus Pfirrmann, Katja Robel, Thomas Illmer, Michael Krämer, Claudia Dill, Gerhard Ehninger, Gabriele Schackert, Dietmar Krex · 2008 · Annals of Oncology
Boron Neutron Capture Therapy: Cellular Targeting of High Linear Energy Transfer Radiation
Jeffrey A. Coderre, Julie Catherine Turcotte, K. J. Riley, Peter J. Binns, O. K. Harling, W. S. Kiger · 2003 · Technology in Cancer Research & Treatment
New treatment strategies for malignant gliomas
Sith Sathornsumetee, Jeremy N. Rich · 2006 · Expert Review of Anticancer Therapy
Cytotoxic Autophagy in Cancer Therapy
Khushboo Sharma, Ngoc Le, Moureq Rashed Alotaibi, David A. Gewirtz · 2014 · International Journal of Molecular Sciences
Glioblastoma vs temozolomide: can the red queen race be won?
Anjali Arora, Kumaravel Somasundaram · 2019 · Cancer Biology & Therapy
How effective is BCNU in recurrent glioblastoma in the modern era?
Alba Ariela Brandes, A. Tosoni, Pietro Amistà, Linda Nicolardi, D. Grosso, Franco Berti, M. Ermani · 2004 · Neurology
Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2
de Gooijer, Mark C., de Vries, Nienke A., Buckle, Tessa, Buil, Levi C.M., Beijnen, Jos H., Boogerd, Willem, van Tellingen, Olaf · 2018 · Neoplasia
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting
Chu, Liuxiang, Wang, Aiping, Ni, Ling, Yan, Xiuju, Song, Yina, Zhao, Mingyu, Sun, Kaoxiang, Mu, Hongjie, Liu, Sha, Wu, Zimei et al. · 2018 · Drug Delivery
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★
Victor A. Levin, Surasak Phuphanich, W.K. Alfred Yung, Peter A. Forsyth, Rolando F. Del Maestro, James Perry, Gregory N. Fuller, Mark Baillet · 2006 · Journal of Neuro-Oncology
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Alba Ariela Brandes, Alicia Tosoni, Umberto Basso, Michele Reni, Francesco Valduga, Silvio Monfardini, Pietro Amistà, Linda Nicolardi, Guido Sotti, Mario Ermani · 2004 · Journal of Clinical Oncology
The role of Stat3 in glioblastoma multiforme
Rodney Brian Luwor, Stanley S. Stylli, Andrew H. Kaye · 2013 · Journal of Clinical Neuroscience
Canadian Recommendations for the Treatment of Glioblastoma Multiforme
Warren P. Mason, Rolando F. Del Maestro, David D. Eisenstat, Peter A. Forsyth, Dorcas S. Fulton, Normand Laperrière, David R. Macdonald, James Perry, Brian Arthur Thiessen · 2007 · Current Oncology
Recent developments in the use of chemotherapy in brain tumours
Martin J. van den Bent, Monika E. Hegi, Roger Stupp · 2006 · European Journal of Cancer
Clinical trial end points for high-grade glioma: the evolving landscape
David A. Reardon, Evanthia Galanis, John F DeGroot, Timothy Francis Cloughesy, Jeffrey Scott Wefel, Kathleen R. Lamborn, A. B. Lassman, Mark R. Gilbert, John Howard Sampson, Wolfgang Wick et al. · 2011 · Neuro-Oncology
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Marc Charles Chamberlain, Sandra K. Johnston · 2009 · Journal of Neuro-Oncology
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Andrew S. Chi, Alma Gregory Sorensen, Rakesh K. Jain, Tracy T. Batchelor · 2009 · The Oncologist
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
G. Evren Keles, Kathleen R. Lamborn, Susan Marina Chang, Michael D. Prados, Mitchel Stuart Berger · 2004 · Journal of neurosurgery
Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
Antonin Dréan, Lauriane Goldwirt, Maïté Verreault, Michael S. Canney, Charlotte Schmitt, Jérémy Guehennec, Jean‐Yves Delattre, Alexandre C. Carpentier, Ahmed Idbaïh · 2016 · Expert Review of Neurotherapeutics
Central Nervous System Cancers
Steven S. Brem, Philip Jay Bierman, Henry Brem, Nicholas Arthur Butowski, Marc Charles Chamberlain, Ennio Antonio Chiocca, Lisa Marie DeAngelis, Robert Alan Fenstermaker, Allan H. Friedman, Mark R. Gilbert et al. · 2011 · Journal of the National Comprehensive Cancer Network
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas
Michael L.H. Wong, Amy Prawira, Andrew Henry Kaye, Christopher M. Hovens · 2009 · Journal of Clinical Neuroscience
Improving the Extent of Malignant Glioma Resection by Dual Intraoperative Visualization Approach
Ilker Yasin Eyüpoglu, Nirjhar Hore, Nicolai E. Savaskan, Peter Grummich, Karl Rössler, Michael Buchfelder, Oliver Ganslandt · 2012 · PLoS ONE
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Michael Badruddoja, James E. Herndon, Jeannette M. Dowell, Allan H. Friedman, Henry S. Friedman · 2004 · Cancer
Recurrent Glioblastoma: Where we stand
Sanjoy Roy, Debarshi Lahiri, Tapas Maji, Jaydip Biswas · 2015 · South Asian Journal of Cancer · Retracted
Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo
Ilker Yasin Eyüpoglu, Eric Hahnen, Rolf Buslei, Florian A. Siebzehnrübl, Nicolai E. Savaskan, Mike Lüders, Christian Tränkle, Wolfgang Wick, Michael Weller, Rudolf Fahlbusch et al. · 2005 · Journal of Neurochemistry
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
Alba Ariela Brandes, Umberto Basso, Michele Reni, Francesca Vastola, Alicia Tosoni, Giovanna Cavallo, Luciano Scopece, Andrés J.M. Ferreri, Maria Grazia Panucci, Silvio Monfardini et al. · 2004 · Journal of Clinical Oncology
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
Mark R. Gilbert, Henry S. Friedman, John F. Kuttesch, Michael D. Prados, Jeffrey J. Olson, Gregory H. Reaman, Sara L. Zaknoen · 2002 · Neuro-Oncology
Bevacizumab and Glioblastoma
Michelle M. Kim, Yoshie Umemura, Denise Leung · 2018 · The Cancer Journal
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)
Maureen Trudeau, Michael Crump, Danielle Charpentier, Louise Yelle, Louise J. Bordeleau, Sarah W. Matthews, Elizabeth A. Eisenhauer · 2006 · Annals of Oncology
Temozolomide: a novel oral alkylating agent
Sarah J. Danson, Mark Ross Middleton · 2001 · Expert Review of Anticancer Therapy
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
Jochen Tuettenberg, Rainer Grobholz, Tobias Korn, Frederik K. Wenz, Ralf Erber, Peter Vajkoczy · 2004 · Journal of Cancer Research and Clinical Oncology
PET for in vivo pharmacokinetic and pharmacodynamic measurements
Nishi Gupta, Pat Price, Eric Ofori Aboagye · 2002 · European Journal of Cancer
Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Julie E Chang, Deepak Khuntia, H. Ian Robins, Minesh P. Mehta · 2007 · PubMed
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
Carsten Nieder, Markus Adam, M. Molls, Anca‐Ligia Grosu · 2006 · Critical Reviews in Oncology/Hematology
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
Philip S. Murphy, Louis Viviers, Charlotte Abson, Ian J. Rowland, Michael Brada, Martin O. Leach, Andrzej S. K. Dzik-Jurasz · 2004 · British Journal of Cancer
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Wolfgang Wick, Antje Wick, Jörg Bernhard Schulz, JOHANNES DICHGANS, H. Peter Rodemann, Michael Weller · 2002 · PubMed
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk M. Koziara, Bartosz Królicki, Maciej Jakuciński, Dariusz Pawlak, Christos Apostolidis, Saed Mirzadeh, Rafał Rola et al. · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk M. Koziara, Bartosz Królicki, Maciej Jakuciński, Dariusz Pawlak, Christos Apostolidis, Saed Mirzadeh, Rafał Rola et al. · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
Diagnosis and Treatment of High-Grade Astrocytoma
Sith Sathornsumetee, Jeremy N. Rich, David A. Reardon · 2007 · Neurologic Clinics
The Role of Topotecan in the Treatment of Brain Metastases
Eric T. Wong, Anna Berkenblit · 2004 · The Oncologist
Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme
Jacob C. Easaw, Warren P. Mason, James Perry, Normand Laperrière, David D. Eisenstat, Rolando F. Del Maestro, Karl Bélanger, Dorcas S. Fulton, David R. Macdonald · 2011 · Current Oncology
Rechallenge with temozolomide in patients with recurrent gliomas
Antje Wick, Christina Pascher, Wolfgang Wick, Tanja Jauch, Michael Weller, Ulrich Bogdahn, Peter Hau · 2009 · Journal of Neurology
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Raja B. Khan, Jeffrey J. Raizer, Mark Gordon Malkin, Kimberley A. Bazylewicz, Lauren E. Abrey · 2002 · Neuro-Oncology
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong, Yin Guo, Ye Liu, Hexiang Wang, Wenfeng Gong, Yong Liu, Xing Wang, Yajuan Gao, Fenglong Yu, Dan Su et al. · 2020 · Neoplasia
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Alberto Broniscer, Lisa C. Iacono, Murali Chintagumpala, Maryam Fouladi, Dana Wallace, Daniel C. Bowers, Clinton F. Stewart, Matthew J. Krasin, Amar J. Gajjar · 2004 · Cancer
Current Chemotherapy for Glioblastoma
Ian F. Parney, Susan Marina Chang · 2003 · The Cancer Journal
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio M. P. Omuro, Timothy An-thy Chan, Lauren E. Abrey, Mustafa Khasraw, Anne S. Reiner, Thomas Joseph Kaley, Lisa Marie DeAngelis, Andrew B. Lassman, Craig P. Nolan, Igor T. Gavrilovic et al. · 2012 · Neuro-Oncology
Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme
Fabian Baumann, Miroslava Bjeljac, Spyros Kollias, Brigitta G. Baumert, Sebastian Brandner, Valentin Rousson, Yasuhiro Yonekawa, René L. Bernays · 2004 · Journal of Neuro-Oncology
Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome
Shiran Ferber, Galia Tiram, Ana Sousa‐Herves, Anat Eldar‐Boock, Adva Krivitsky, Anna Scomparin, Eilam Yeini, Paula Ofek, Dikla Ben‐Shushan, Laura Isabel Vossen et al. · 2017 · eLife
Temozolomide: a milestone in neuro-oncology and beyond?
Nicole Mutter, Roger Stupp · 2006 · Expert Review of Anticancer Therapy
Obstacles to Brain Tumor Therapy: Key ABC Transporters
Juwina Wijaya, Yu Fukuda, John D. Schuetz · 2017 · International Journal of Molecular Sciences
Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy
Tobias Neff, Brian C. Beard, Laura J. Peterson, Ponni Anandakumar, Jesse Thompson, Hans‐Peter Kiem · 2004 · Blood
Anaplastic astrocytoma in adults
Roger Stupp, Michele Reni, Gemma Gatta, Elena A. Mazza, Charles J. Vecht · 2007 · Critical Reviews in Oncology/Hematology
Dose‐dense temozolomide regimens
Bart Neyns, Alicia Tosoni, Wen‐Jen Hwu, David A. Reardon · 2010 · Cancer
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John Howard Sampson, Jeremy N. Rich, Roger E. McLendon, James E. Herndon, Jennifer E. Marcello, Stevie Threatt et al. · 2010 · Journal of Neuro-Oncology
VEGF in Tumor Progression and Targeted Therapy
Vladimir Pavlovich Chekhonin, Sergey A. Shein, Anna A. Korchagina, Olga Ivanovna Gurina · 2013 · Current Cancer Drug Targets
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
Motoo Nagane, Ryo Nishikawa, Yusuke Narita, H. Kobayashi, Shingo Takano, Nobusada Shinoura, Taku Aoki, Keiji Sugiyama, J. Kuratsu, Yoshihiro Muragaki et al. · 2012 · Japanese Journal of Clinical Oncology
Targeting malignant glioma survival signalling to improve clinical outcomes
Michael L.H. Wong, Andrew Henry Kaye, Christopher M. Hovens · 2007 · Journal of Clinical Neuroscience
Chemotherapy in glioma
Walter Taal, Jacoline E. C. Bromberg, Martin J. van den Bent · 2015 · CNS Oncology
Management of malignant glioma: steady progress with multimodal approaches
Lynn Stuart Ashby, Timothy Charles Ryken · 2006 · Neurosurgical FOCUS
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J. Clarke, Evan A. Mulligan, Patrick Thomas Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu et al. · 2009 · Molecular Cancer Therapeutics
A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma
Susan M. Talbot, Mary Louise Keohan, Mary E. Hesdorffer, Russell Orrico, Emilia Bagiella, Andrea B. Troxel, Robert N. Taub · 2003 · Cancer
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol
Stephanie Elisabeth Combs, Steffen Heeger, Renate Haselmann, Lutz Edler, Jürgen Debus, Daniela Schulz–Ertner · 2006 · BMC Cancer
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
Kathryn P. Beal, Lauren E. Abrey, Philip H. Gutin · 2011 · Radiation Oncology
Neurologic complications of cancer therapy
Scott Randall Plotkin, Patrick Yung Wen · 2003 · Neurologic Clinics
Headaches and brain tumors
R. Allan Purdy, Sarah Kirby · 2004 · Neurologic Clinics
Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review)
Xiang Zhang, Wei Zhang, Weidong Cao, Gang Cheng, Yongqiang Zhang · 2011 · Experimental and Therapeutic Medicine
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma
Dapeng Wang, Anders Berglund, Rajappa S. Kenchappa, Peter A. Forsyth, James J. Mulé, Arnold B. Etame · 2016 · Scientific Reports
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
Jacob Joseph Mandel, Shlomit Yust‐Katz, Akash J. Patel, David Cachia, Diane Liu, Minjeong Park, Ying Yuan, Thomas A. Kent, John de Groot · 2017 · Neuro-Oncology
Bevacizumab for the Treatment of Glioblastoma
Miguel Gil‐Gil, Carlos Mesía, Montserrat Rey, Jordi Bruna · 2013 · Clinical Medicine Insights Oncology
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
David A. Reardon, Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan Hendrik Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, Henry S. Friedman · 2009 · Cancer